Thu, Nov 27, 2014, 11:22 AM EST - U.S. Markets closed for Thanksgiving Day

Recent

% | $
Quotes you view appear here for quick access.

Roche Holding AG Message Board

  • dooom.booom dooom.booom Mar 15, 2014 8:50 AM Flag

    Zybrestat and Avastin reduced the risk of tumor regrowth or death (progression-free survival) by 32% compared to Avastin alone.

    Oxigene Positive Ovarian Cancer Study Success ZYBRESTAT Topical, a reformulation aimed at ophthalmological disorders has the potential to address a market of $390 billion in age related macular

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • A. H over $ 5 get ready

      Sentiment: Strong Buy

    • Oxigene Positive Ovarian Cancer Study Success ZYBRESTAT Topical, a reformulation aimed at ophthalmological disorders has the potential to address a market of $390 billion in age related macular degeneration (AMD) and Polypoidal Choroidal Vasculopathy (PCV)*** OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancers, such as ovarian and certain thyroid cancers. The Company’s major focus is developing vascular disrupting agents (VDAs) that selectively disrupt abnormal blood vessels associated with solid tumors. OXiGENE is dedicated to leveraging its scientific expertise, intellectual property and therapeutic development capabilities to bring life-extending and life-enhancing medicines to patients.*** About VDAs Vascular Disrupting Agents or “VDAs” block blood flow through established tumor blood vessels, thereby starving tumors of oxygen and essential nutrients, leading to tumor cell death.**** The phase II study, conducted by the non-profit Gynecologic Oncology Group, not Oxigene, enrolled 107 women with platinum-sensitive and resistant, recurrent ovarian cancer. The patients were randomized to receive either Roche's Avastin alone, or a combination of Zybrestat and Avastin. On the study's primary endpoint, the combination of Zybrestat and Avastin reduced the risk of tumor regrowth or death (progression-free survival) by 32% compared to Avastin alone. The result was very statistically significant. OXiGENE’s Development Pipeline is comparable with Celldex pipeline Here's some information taken directly from the OxiGENE BIO CEO Conference presentation. Current chemotherapy is notorious for killing healthy cells along with cancerous ones – The Zybrestat/Avastin combination is designed to change that. Zybrestat kills tumor cells by selectively blocking the blood vessels that carry vital oxygen and nutrients to tumors. Let's keep it simple and give you these Fact Results: One-year survival rate 25.5% vs. 8.7%

      Sentiment: Strong Buy

      • 1 Reply to dooom.booom
      • Zybrestat kills tumor cells by selectively blocking the blood vessels that carry vital oxygen and nutrients to tumors. Let's keep it simple and give you these Fact Results: One-year survival rate 25.5% vs. 8.7% Median Overall Survival 5.2 vs. 4.0 months (HR 0.72) 25% higher Objective Response rate (20% vs. 16%) VDAs reduced blood flow to the center of the tumors by 70% **** more information please visit OXIGENE H.P :

        Sentiment: Strong Buy

 
RHHBY
37.41+0.20(+0.54%)Nov 26 3:58 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
SeaDrill Limited
NYSEWed, Nov 26, 2014 4:01 PM EST
AGCO Corporation
NYSEWed, Nov 26, 2014 4:05 PM EST